CD274 and laryngotracheoesophageal cleft: assessed the association between ICI use and TB development, reporting 16 LC patients developing active TB during PD‐(L)1 inhibitor treatment, with a median time to TB recurrence of 6.3 months after starting ICI treatment [28].